论文部分内容阅读
目的:观察胺碘酮治疗急性心肌梗死(AMI)并心房颤动(房颤)的临床疗效及安全性。方法:对52例AMI并房颤患者首剂静脉注射胺碘酮150 mg,随后以0.5~1.5 mg/min维持静脉滴注,静脉用药2~6(3.15±1.2)mg/d。结果:房颤转复率2 h内为51.9%(27/52),24 h内为75.0%(39/52),48 h内为88.5%(46/52),72 h内为92.3%(48/52)。治疗期间,6例(11.5%)出现窦性心动过缓,减量后心率恢复;5例出现血压偏低,减量后血压恢复正常。结论:静脉注射胺碘酮对AMI并房颤疗效明显,未见严重不良反应。
Objective: To observe the clinical efficacy and safety of amiodarone in the treatment of acute myocardial infarction (AMI) and atrial fibrillation (AF). Methods: Fifty-two patients with AMI and atrial fibrillation were intravenously injected with the first dose of amiodarone 150 mg, followed by intravenous infusion of 0.5-1.5 mg / min intravenously for 2-6 (3.15 ± 1.2) mg / d. Results: The recovery rate of atrial fibrillation was 51.9% (27/52) in 2 h, 75.0% (39/52) in 24 h, 88.5% (46/52) in 48 h and 92.3% in 72 h 48/52). During treatment, sinus bradycardia occurred in 6 cases (11.5%), and heart rate recovered after reduction. Blood pressure was low in 5 cases and blood pressure returned to normal after reduction. Conclusion: Amiodarone intravenous injection of AMI and atrial fibrillation obvious effect, no serious adverse reactions.